Pembrolizumab in combination with chemotherapy is already FDA-approved for the treatment of patients with triple-negative breast cancer – in the setting of early or metastatic diseases. […]
Previous data showed that the addition of pembrolizumab to neoadjuvant chemotherapy led to a significantly higher percentage of patients with early triple-negative breast cancer (TNBC) having […]
Clinical Oncologist at Grupo Oncoclínicas discusses phase II DESTINY-Breast01 study and meta-analysis that included four randomized clinical trials involving patients with triple-negative breast cancer The ESMO Breast Cancer 2021 event, held […]
Currently available genetic tests analyzing homologous recombination deficiency (HRD) have limited predictive value During the ESMO Breast Cancer 2021 Congress, in virtual format, a retrospective […]
Most breast cancers exhibit low T–lymphocyte infiltration and do not respond satisfactorily to immune correceptor inhibitors, leading to the need for new therapeutic strategies that act on anti-tumor immune […]
Presented during ESMO Breast Cancer 2021, meta-analysis approaches immune checkpoint inhibitors (ICIs), which have shown promising antitumor activities in several malignancies ESMO Breast Cancer 2021 starts today in virtual format, a […]
Triple-negative breast cancer is an aggressive tumor with lower overall survival compared to other types of breast malignancies. Of the 6 molecularly classified TNBC subtypes, about 10 to […]
Radiotherapy after breast-conserving surgery for the treatment of ductal carcinoma in situ (DCIS) reduces the risk of ipsilateral breast events without changing survival Between March 18th and 19th, SSO 2021 (International Conference […]
New therapeutic option for patients with high-risk HR-positive, HER2-negative breast cancer Abemaciclib in combination with standard adjuvant endocrine therapy (ET) achieved its primary objective in the […]